A5025688165- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Multiple and Secondary Primary Cancers
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Polyomavirus and related diseases
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- T-cell and Retrovirus Studies
- Monoclonal and Polyclonal Antibodies Research
- Ovarian cancer diagnosis and treatment
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- Glioma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
Mayo Clinic in Arizona
2016-2025
Mayo Clinic
2016-2025
WinnMed
2015-2025
Neurological Institute of Thailand
2024
Mayo Clinic in Florida
1983-2024
Calabazas Creek Research (United States)
2023-2024
University of Minnesota Rochester
1994-2023
University of South Florida
2023
Kite (United States)
2023
Medical University of Silesia
2023
Medical errors are associated with feelings of distress in physicians, but little is known about the magnitude and direction these associations.To assess frequency self-perceived medical among resident physicians to determine association quality life, burnout, depression, empathy using validated metrics.Prospective longitudinal cohort study categorical preliminary internal medicine residents at Mayo Clinic Rochester. Data were provided by 184 (84%) 219 eligible residents. Participants began...
Purpose To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a two-stage randomized trial of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) versus rituximab plus CHOP (R-CHOP), second random assignment to maintenance (MR) or observation responding patients. Patients Methods Untreated DLBCL who were 60 years randomly assigned R-CHOP (n = 318) 314); 415 responders MR 207) 208). The primary end point was...
To gain insight into the genomic basis of diffuse large B-cell lymphoma (DLBCL), we performed massively parallel whole-exome sequencing 55 primary tumor samples from patients with DLBCL and matched normal tissue. We identified recurrent mutations in genes that are well known to be functionally relevant DLBCL, including MYD88 , CARD11 EZH2 CREBBP . also somatic for which a functional role has not been previously suspected. These include MEF2B MLL2 BTG1 GNA13 ACTB P2RY8 PCLO TNFRSF14 Further,...
<h3>Context</h3>Fatigue and distress have been separately shown to be associated with medical errors. The contribution of each factor when assessed simultaneously is unknown.<h3>Objective</h3>To determine the association fatigue self-perceived major errors among resident physicians using validated metrics.<h3>Design, Setting, Participants</h3>Prospective longitudinal cohort study categorical preliminary internal medicine residents at Mayo Clinic, Rochester, Minnesota. Data were provided by...
Posttransplantation lymphoproliferative disorder (PTLD) is an uncommon but often fatal complication of solid organ transplantation that occurs in approximately 3% patients. To determine the relative importance and relationship potential risk factors for PTLD before (i.e., Epstein-Barr virus [EBV] serostatus recipient cytomegalovirus [CMV] sero-status donor) principal factor after (immunosuppression with antilymphocyte antibody), we analyzed findings first 381 consecutive adult nonrenal...
The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity a variety hematologic malignancies, including non-Hodgkin's (NHL). We report the results phase II, single-arm, multicenter trial evaluating safety and efficacy lenalidomide oral monotherapy patients with relapsed refractory NHL.Patients were treated 25 mg once daily on days 1 21, every 28 days, for 52 weeks, until disease progression intolerance. primary end point was...
Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death commonly used as the events. We timing type events in newly diagnosed DLBCL compared patient outcome reference population data.Patients treated immunochemotherapy were prospectively enrolled onto University Iowa/Mayo Clinic Specialized Program Research Excellence Molecular Epidemiology Resource (MER) North Central Cancer Treatment Group NCCTG-N0489...
Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone); this new combination is known as R2CHOP. The goal of phase II study was to evaluate the efficacy newly diagnosed DLBCL.Eligible patients were adults untreated stages IV CD20(+) DLBCL. Patients received 25 mg orally per day on days 1 through 10...
The growth of non-Hodgkin lymphomas can be influenced by tumor-immune system interactions. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative regulator T-cell activation that serves to dampen antitumor immune responses. Blocking anti-CTLA-4 monoclonal antibodies improves host resistance immunogenic tumors, and the antibody ipilimumab (MDX-010) has clinical activity against melanoma, prostate, ovarian cancers.We did phase I trial in patients with relapsed/refractory B-cell lymphoma...
The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). goal this trial was to learn antitumor activity and toxicity single-agent everolimus relapsed/refractory aggressive NHL. Patients received 10 mg PO daily. Response assessed after two six cycles, then every three cycles until progression. A total 77...
This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use.
Purpose Although ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of care in patients with advanced Hodgkin lymphoma, newer regimens have investigated, which appeared superior early phase II studies. Our aim was to determine if failure-free survival treated Stanford V regimen compared ABVD. Patients Methods The Eastern Cooperative Oncology Group, along Cancer Leukemia Group B, Southwest Canadian NCIC Clinical Trials conducted this randomized...
To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma.Patients with stage III-IV lymphoma responding or stable disease cyclophosphamide, vincristine, and prednisone (CVP) were stratified by initial tumor burden, residual CVP (minimal gross), histology, randomly assigned to observation (OBS) MR 375 mg/m(2) once per week for 4 weeks every 6 months 2 years. PFS was the primary end point.Three hundred...
The World Health Organization classification of non-Hodgkin lymphoma (NHL) was introduced in 2001. However, its incorporation into clinical practice is not well-described. We studied the distribution NHL subtypes adults diagnosed from 1998 to 2011, evaluated time trends, geo-demographic correlates, and changes 5-year overall survival (OS). obtained data prospectively collected by National Cancer Data Base, which covers 70% US cancer cases. There were 596,476 patients with NHL. major diffuse...